Federico Bertoletti

Statistics

Publications

Citations

238

H-Index

Active since

2004

Affiliations

Hospital de Sant Pau(Current)

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Hospital Universitario Fundación Alcorcón

Hospital Universitario Infanta Sofía

Hospital Universitario de Fuenlabrada

Federico Bertoletti is an author at Hospital de Sant Pau specializing in inflammatory bowel disease, pharmacotherapy, and inflammatory bowel disease therapy.

Publications per year

2004–2023

Publications

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

Carlos Taxonera, Cristina Rodríguez, Federico Bertoletti et al. · Inflammatory Bowel Diseases · 2017 · 80 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

Alicia Algaba, Iván Guerra, Elena Ricart et al. · Digestive Diseases and Sciences · 2020 · 51 citations

Medicine, Clinical Sciences, Internal Medicine +14

Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn’s Disease (Versus-CD): Data from the ENEIDA Registry

María José García, Montserrat Rivero, A Fernández-Clotet et al. · Journal of Crohn s and Colitis · 2023 · 19 citations

Pharmacy, Immunology, Pharmacotherapy +15

Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis

Carlos Taxonera, Marisa Iborra, Marta Maia Boscá-Watts et al. · Current Medical Research and Opinion · 2019 · 18 citations

Medicine, Immunology, Pharmacotherapy +17

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

Marisa Iborra, Natalia García‐Morales, S Rubio et al. · Scientific Reports · 2020 · 17 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +13

1–5 of 9